Omeros (NASDAQ:OMER) Rating Increased to Strong-Buy at RODMAN&RENSHAW

RODMAN&RENSHAW upgraded shares of Omeros (NASDAQ:OMER) to a strong-buy rating in a research report report published on Thursday morning,Zacks.com reports.

Other equities research analysts also recently issued research reports about the company. Rodman & Renshaw initiated coverage on Omeros in a research report on Thursday. They issued a “buy” rating and a $9.00 price objective on the stock. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Omeros in a report on Thursday. StockNews.com lowered Omeros from a “hold” rating to a “sell” rating in a report on Tuesday, November 12th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research note on Thursday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $9.00.

Omeros Trading Down 2.9 %

Omeros stock opened at $6.75 on Thursday. The firm’s 50 day simple moving average is $4.14 and its 200 day simple moving average is $4.11. Omeros has a 1-year low of $1.38 and a 1-year high of $7.51. The firm has a market capitalization of $391.16 million, a PE ratio of -2.92 and a beta of 1.47.

Institutional Trading of Omeros

Hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets lifted its holdings in shares of Omeros by 75.5% in the 1st quarter. BNP Paribas Financial Markets now owns 30,102 shares of the biopharmaceutical company’s stock worth $104,000 after acquiring an additional 12,951 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new stake in Omeros during the first quarter valued at about $85,000. Comerica Bank increased its holdings in shares of Omeros by 20.0% in the first quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 5,000 shares during the period. Vanguard Group Inc. lifted its stake in shares of Omeros by 2.6% in the 1st quarter. Vanguard Group Inc. now owns 3,250,284 shares of the biopharmaceutical company’s stock valued at $11,213,000 after acquiring an additional 81,348 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in Omeros by 16.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock valued at $887,000 after acquiring an additional 31,081 shares during the period. Institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.